



PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Date: 13th November, 2018

**To,
National Stock Exchange of India Limited,
Exchange Plaza,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai- 400051**

Sub: - Outcome of Board Meeting held on 13th November, 2018

Dear Sir,

A meeting of the Board of Directors of the company was held on Tuesday, the 13th day of November, 2018 at 11.30 a.m. at the Corporate Office of the Company and concluded at 3.35 p.m. The Board *inter-alia* considered and approved the Unaudited Financial Results (both Standalone and Consolidated) of the company for the second quarter of the financial year 2018-19 ended on 30th September, 2018.


Pursuant to the provisions of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find attached herewith, the Unaudited Financial Results (Standalone and Consolidated basis) as on 30th September, 2018 of the Company along with the Limited Review Report given by the Statutory Auditors of the Company on the Unaudited Financial Results for the quarter ended on 30th September, 2018.

This is for the information of the exchange and members thereof.

You are requested to take the same on record.

Thanking You

For Parenteral Drugs (India) Limited


**Vinod Kumar Gupta
Managing Director
(DIN: 00039145)**





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

Sr. No.	Particulars	(Rs in Lakh, unless otherwise stated)					
		Quarter Ended 30-09-2018 (Unaudited)	Quarter Ended 30-06-2018 (Unaudited)	Quarter Ended 30-09-2017 (Unaudited)	Year to Date 30-09-2018 (Unaudited)	Year to Date 30-09-2017 (Unaudited)	Year Ended 31-03-2018 (Audited)
	Income						
I	(a) Revenue From Operation (Gross)	889.49	1,056.32	1,082.17	1,945.81	2,193.29	3,297.13
II	(b) Other Operating Income	0.93	2.41	26.14	3.34	89.83	134.41
III	Total Income (I+II)	890.42	1,058.73	1,108.31	1,949.15	2,283.12	3,431.54
IV	Expenditure						
	Cost of Material Consumed	280.87	196.18	149.68	477.05	257.13	439.20
	Purchase of Stock In Trade	-	-	38.66	-	123.33	131.15
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	(75.61)	(46.79)	(71.96)	(122.40)	(48.90)	105.82
	Employee Benefit Expenses	490.43	497.83	372.43	988.26	764.90	1,669.69
	Finance costs	2,385.93	2,285.46	2,215.27	4,671.39	4,236.70	8,634.00
	Depreciation, Amortisation and Impairment Expenses	463.43	464.89	452.68	928.32	905.36	1,856.65
	Other Expenditure	578.20	637.44	857.73	1,215.64	1,646.25	2,535.30
	Total Expenses (IV)	4,123.25	4,035.01	4,014.49	8,158.26	7,884.77	15,371.81
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(3,232.83)	(2,976.28)	(2,906.18)	(6,209.11)	(5,601.65)	(11,940.27)
VI	Exceptional items	-	-	-	-	-	-
VII	Profit / (Loss) before Tax (V-VI)	(3,232.83)	(2,976.28)	(2,906.18)	(6,209.11)	(5,601.65)	(11,940.27)
VIII	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	(546.86)	(592.25)	(635.29)	(1,139.11)	(1,189.60)	(2,331.05)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,685.97)	(2,384.03)	(2,270.89)	(5,070.00)	(4,412.05)	(9,609.22)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)						
XIII	Profit/(loss) for the period (IX+XII)	(2,685.97)	(2,384.03)	(2,270.89)	(5,070.00)	(4,412.05)	(9,609.22)
XIV	Other Comprehensive Income						
	A (i) Item that will not be reclassified to Profit or loss	(1.09)	(1.09)	(60.06)	(2.18)	(60.50)	(2.31)
	(ii) Income tax relation to Item that will not be reclassified to Profit or loss	-	-	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV) (comprising profit (loss) and other comprehensive income for the period)	(2,687.06)	(2,385.12)	(2,330.95)	(5,072.18)	(4,472.55)	(9,611.53)
XVI	Paid Up Equity share capital (Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation):						
	(a) Basic (In Rs)	(9.01)	(8.00)	(7.82)	(17.01)	(15.00)	(32.24)
	(b) Diluted (In Rs)	(9.01)	(8.00)	(7.82)	(17.01)	(15.00)	(32.24)
XVIII	Earnings per share (for discontinued operation):						
	(a) Basic (In Rs)	-	-	-	-	-	-
	(b) Diluted (In Rs)	-	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation):						
	(a) Basic (In Rs)	(9.01)	(8.00)	(7.82)	(17.01)	(15.00)	(32.24)
	(b) Diluted (In Rs)	(9.01)	(8.00)	(7.82)	(17.01)	(15.00)	(32.24)



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;

Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;

CIN: L24100MH1983PLC126481



JAS-ANZ





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com


Sr. No.	Statement of Assets and Liabilities: Particulars	STANDALONE	
		As at 30-09-2018 (Unaudited)	As at 31-03-2018 (Audited)
I.	ASSETS		
(1)	Non-current assets		
	(a) Property, plant and equipment	60,764.06	61,692.39
	(b) Intangible assets	-	-
	(c) Financial Assets		
	(i) Investments	257.85	257.85
	(ii) Loans	260.00	258.50
	(iii) Others	4.84	4.84
	(d) Other non-current assets	613.28	567.52
	(e) Deferred tax assets(Net)	8,316.92	7,176.99
	Total Non-current assets	70,216.95	69,958.09
(2)	Current assets		
	(a) Inventories	231.20	124.85
	(b) Financial Assets		
	(i) Investments	-	-
	(ii) Trade receivables	5,690.41	5,706.89
	(iii) Cash and cash equivalents	3.10	0.66
	(iv) Bank balances other than (iii) above	76.86	76.86
	(v) Loans	498.44	496.62
	(c) Other Current Assets	98.14	68.64
	Total Current assets	6,598.15	6,474.52
	Total Assets	76,815.10	76,432.61
II.	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	2,981.63	2,981.63
	(b) Other Equity	(18,831.39)	(13,759.21)
	Total Equity	(15,849.76)	(10,777.58)
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	30,499.94	34,051.54
	(ii) Other financial liabilities	-	-
	(b) Other non-current liabilities	15.75	16.50
	Total Non-Current Liabilities	30,515.69	34,068.04
(2)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	12,793.54	12,793.54
	(ii) Trade payables	1,339.92	1,357.40
	(iii) Other financial liabilities	43,461.75	35,278.68
	(b) Other current liabilities	3,800.51	2,987.11
	(c) Provisions	753.45	725.42
	Total Current liabilities	62,149.17	53,142.15
	Total Equity and Liabilities	76,815.10	76,432.61

Notes to the financial results:

- The above results were reviewed by the audit committee at their meeting held on 12-11-2018 and thereafter approved by Board of Directors at their meeting held on 13-11-2018.
- The statutory auditors of the company have carried out limited review of the aforesaid results.
- The above standalone financial results for the quarter and half year ended on 30th September 2018 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- The previous period figures have been regrouped/rearranged wherever found necessary.
- The Standalone financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

Place: Indore
Date: 13th November 2018

Vinod Kumar Gupta
Managing Director
DIN 00039145



Corp. Office: Shree Ganesh Chambers, A.B. Road, Navlakha Crossing,
Indore-452 001 (M.P.) India; Ph.: (0731) 4092000, 6652000-03;
Fax: (0731) 2401052; E-mail: pdpl@pdindia.com;
CIN: L24100MH1983PLC126481





Standalone Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** for the quarter and half year ended 30th September, 2018 attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 13-11-2018

For Singhal Jain & Co.

Chartered Accountants

Kamal Jain

CA Kamal Jain
(Partner)

M. No. 406604

F.R.N.013995C





PARENTERAL DRUGS (INDIA) LIMITED


Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office : 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (W), Mumbai

UN AUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER, 2018

Sr. No.	Particulars	(Rs in Lakh)					
		Quarter Ended 30-09-2018 (Unaudited)	Quarter Ended 30-06-2018 (Unaudited)	Quarter Ended 30-09-2017 (Unaudited)	Year to Date 30-09-2018 (Unaudited)	Year to Date 30-09-2017 (Unaudited)	Year Ended 31-03-2018 (Audited)
		Refer note no.6			Refer note no.6		
I	(a) Revenue From Operation	889.49	4908.06	7,358.85	1945.81	13603.03	21711.04
II	(b) Other Income	0.93	16.74	25.20	3.34	96.49	159.27
III	Total Income (I+II)	890.42	4924.80	7384.05	1949.15	13699.52	21870.31
IV	Expenditure						
	Cost of Material Consumed	280.87	2872.79	2,418.32	477.05	4770.03	7125.99
	Purchase of Stock In Trade	0.00	192.62	1,508.40	0.00	3864.19	6655.52
	Change in Inventories of Finished Goods, Stock In trade and Work in Progress	-75.61	-764.25	732.67	-122.40	908.47	1860.45
	Employee Benefit Expenses	490.43	678.55	493.78	988.26	1003.16	2193.49
	Finance costs	2385.93	2555.07	2,527.96	4671.39	4835.76	9754.26
	Depreciation and Amortisation Expenses	463.43	606.84	602.40	928.32	1204.81	2424.33
	Other Expenditure	578.20	1815.22	2,674.08	1215.64	4391.08	5981.24
	Total Expenses (IV)	4123.25	7956.84	10957.61	8158.26	20977.49	35995.28
V	Profit / (Loss) before exceptional items and Tax (I-IV)	(3,232.83)	(3,032.04)	(3,573.56)	(6,209.11)	(7,277.97)	(14,124.97)
VI	Exceptional items						
VII	Profit / (Loss) before Tax (V-VI)	(3,232.83)	(3,032.04)	(3,573.56)	(6,209.11)	(7,277.97)	(14,124.97)
VIII	Tax Expenses						
	(1) Current Tax	-	-	-	-	-	-
	(2) Deferred Tax	(546.86)	(574.19)	(608.71)	(1139.11)	(1135.95)	(2230.77)
IX	Net Profit / (Loss) for the period from continuing operations (VII-VIII)	(2,685.97)	(2,457.85)	(2,964.85)	(5,070.00)	(6,142.02)	(11,894.20)
X	Net Profit / (Loss) for the period from discontinuing operations	-	-	-	-	-	-
XI	Tax expense of discontinuing operations	-	-	-	-	-	-
XII	Net Profit / (Loss) from discontinued operations (after Tax) (X-XI)	-	-	-	-	-	-
XIII	Profit/(loss) for the period (IX+XII)	(2,685.97)	(2,457.85)	(2,964.85)	(5,070.00)	(6,142.02)	(11,894.20)
XIV	Other Comprehensive Income						
	A (i) Item that will not be reclassified to Profit or loss	(1.09)	(0.36)	(60.06)	(2.18)	(60.50)	(5.08)
	(ii) Income tax relation to Item that will not be reclassified	-	-	-	-	-	-
	B (i) Item that will be reclassified to Profit or loss	-	-	-	-	-	-
	(ii) Income tax relation to Item that will be reclassified to Profit or loss	-	-	-	-	-	-
XV	Total comprehensive Income for the period (XIII+XIV)(comprising profit (loss) and other comprehensive income for the period)	(2,687.06)	(2,458.21)	(3,024.91)	(5,072.18)	(6,202.52)	(11,899.28)
XVI	Paid Up Equity share capital(Face value Rs.10/-each)	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63	2,981.63
XVII	Earnings per share (for continuing operation) :						
	(a) Basic	(9.01)	(8.24)	(10.15)	(17.01)	(20.80)	(39.91)
	(b) Diluted	(9.01)	(8.24)	(10.15)	(17.01)	(20.80)	(39.91)
XVIII	Earnings per share (for discontinued operation) :						
	(a) Basic	-	-	-	-	-	-
	(b) Diluted	-	-	-	-	-	-
XIX	Earnings per share (for discontinued & continuing operation) :						
	(a) Basic	(9.01)	(8.24)	(10.15)	(17.01)	(20.80)	(39.91)
	(b) Diluted	(9.01)	(8.24)	(10.15)	(17.01)	(20.80)	(39.91)





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Sr. No.	Statement of Assets and Liabilities: Particulars	Consolidated	
		As at 30-09-2018 (Unaudited)	As at 31-03-2018 (Audited)
I.	ASSETS		
(1)	Non-current assets		
	(a) Property, plant and equipment	60,764.06	71,580.42
	(b) Intangible assets	-	-
	(c) Financial Assets	-	-
	(i) Investments	240.10	0.10
	(ii) Loans	260.25	385.84
	(iii) Others	4.84	8.90
	(d) Other non-current assets	698.70	770.69
	(e) Deferred tax assets(net)	8,316.92	6,391.48
	Total Non-current assets	70,284.87	79,137.43
(2)	Current assets		
	(a) Inventories	231.20	2,701.43
	(b) Financial Assets	-	-
	(i) Investments	-	-
	(ii) Trade receivables	5,690.41	6,036.48
	(iii) Cash and cash equivalents	3.30	7.64
	(iv) Bank balances ther than (iii) above	76.86	347.22
	(v) Loans	498.44	565.38
	(c) Other Current Assets	171.23	246.65
	Total Current assets	6,671.44	9,904.80
	Total Assets	76,956.31	89,042.23
II.	EQUITY AND LIABILITIES		
	Equity		
	(a) Equity share capital	2,981.63	2,981.63
	(b) Other Equity	(18,814.53)	(16,625.37)
	Total Equity	(15,832.90)	(13,643.74)
	Minority Interest	28.30	28.37
	LIABILITIES		
(1)	Non-Current Liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	30,595.87	43,384.78
	(ii) Other financial liabilities	-	-
	(b) Other non-current liabilities	15.75	16.50
	Total Non-Current Liabilities	30,611.62	43,401.28
(2)	Current liabilities		
	(a) Financial Liabilities		
	(i) Borrowings	12,793.54	15,336.10
	(ii) Trade payables	1,340.04	5,119.55
	(iii) Other financial liabilities	43,461.75	36,255.67
	(b) Other current liabilities	3,800.51	1,703.61
	(c) Provisions	753.45	841.39
	Total Current liabilities	62,149.29	59,256.32
	Tota Equity and Liabilities	76,956.31	89,042.23





PARENTERAL DRUGS (INDIA) LIMITED

Regd. Office: 340, Laxmi Plaza, Laxmi Industrial Estate, New Link Road, Andheri (West), Mumbai-400 053 (MH) India;
Tel.: (022) 61725900-01; Fax: (022) 26333763; E-mail: pdpl_mumbai@pdindia.com; Website: www.pdindia.com

Notes to the financial results:

- 1 The above results were reviewed by the audit committee at their meeting held on 12-11-2018 and thereafter approved by Board of Directors at their meeting
- 2 The statutory auditors of the company have carried out limited review of the aforesaid results.
- 3 Additional information on standalone financial results are given below:


Particulars	Rs. In Lakh					
	Quarter Ended 30-09-2018 (Unaudited)	Quarter Ended 30-06-2018 (Unaudited)	Quarter Ended 30-09-2017 (Unaudited)	Year to Date 30-09-2018 (Unaudited)	Year to Date 30-09-2017 (Unaudited)	Year ended 31-03-2018 (Audited)
Total Income from operations	890.42	1,058.73	1,108.31	1,949.15	2,283.12	3,431.54
Profit/Loss before tax	(3,232.83)	(2,976.28)	(2,906.18)	(6,209.11)	(5,601.65)	(11,940.27)
Profit/Loss after tax	(2,687.06)	(2,385.12)	(2,330.95)	(5,072.18)	(4,472.55)	(9,611.53)

- 4 The Consolidated financial results for the quarter and half year ended on September 30, 2018 have been prepared in accordance with the Companies (Indian Accounting Standard) Rules, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable beginning April 1, 2017, the Company has for the first time adopted Ind AS with the transition date of April 1, 2016.
- 5 At the moment the Company is having only one reportable segment in accordance with Ind AS 108 (segment reporting) as the business under proposed real estate segment is yet to commence.
- 6 Figures of quarter ended September 2018 and Year to date do not include the figures of subsidiary company Infutec Healthcare Limited as it has a subsidiary w.e.f. 10-07-2018, hence figures are not comparable with previous corresponding period.
- 7 The previous period figures have been regrouped/rearranged wherever found necessary.
- 8 The Consolidated financial results of the Company are available on the web site of the company i.e. www.pdindia.com and on website of the BSE (www.bseindia.com) & NSE (www.nseindia.com)

For & on behalf of the Board of Directors

Place: Indore
Date: 13th November 2018

Vinod Kumar Gupta
Managing Director
DIN 00039145





Consolidated Limited Review Report

Limited Review Report to

The Board of Directors of Parenteral Drugs (India) Limited

We have reviewed the accompanying statement of unaudited financial results of **Parenteral Drugs (India) Limited** and its subsidiaries for the quarter and half year ended **30th September, 2018** attached herewith, being submitted by the company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial statements based on our review.

We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information performed by the Independent auditor of the entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement.

A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

The financial results and other financial information of the subsidiaries have not been subjected to review and have been presented based on the financial information compiled by the company.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards i.e. IND AS prescribed under section 133 of the Companies Act, 2013 read with relevant rules issued there under and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Indore

Date: 13-11-2018

For Singhal Jain & Co.

Chartered Accountants


CA Kamal Jain
(Partner)



M. No. 406604

F.R.N.013995C